Author

Lijian Feng

Novartis (China)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

Bin XiangiD· 1 shared Bisi Miao· 1 shared Chenxi HeiD· 1 shared En LiiD· 1 shared Fei LaniD· 1 shared Jia FaniD· 1 shared Jiabin CaiiD· 1 shared Jiajia CheniD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bin XiangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

Bisi Miao, Ling Ge, Chenxi He, Xinghao Wang, Jibo Wu, Xiang Li, Kun Chen, Jinkai Wan, Shenghui Xing, Lingnan Ren, Zhennan Shi, Shengnan Liu, Yajun Hu, Jiajia Chen, Yanyan Yu, , Fei Lan

This study identifies SMYD5 as a methyltransferase that modifies RPL40 K22me3, enhancing translation and promoting hepatocellular carcinoma.

Cell Research · Aug 5, 2024Peer-reviewedCancer Biology